← Back to Search
Occurrence And Outcome Of De Novo Metastatic Breast Cancer By Subtype In A Large, Diverse Population
Li Tao, L. Chu, L. Wang, Lisa M. Moy, M. Brammer, Chunyan Song, M. Green, A. Kurian, S. Gomez, C. Clarke
Published 2016 · Medicine
Download PDFAnalyze on Scholarcy
PurposeTo examine the occurrence and outcomes of de novo metastatic (Stage IV) breast cancer, particularly with respect to tumor HER2 expression.MethodsWe studied all 6,268 de novo metastatic breast cancer cases diagnosed from 1 January 2005 to 31 December 2011 and reported to the California Cancer Registry. Molecular subtypes were classified according to HER2 and hormone receptor (HR, including estrogen and/or progesterone receptor) expression. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) of Stage IV versus Stage I–III breast cancer; Cox proportional hazards regression was used to assess relative hazard (RH) of mortality.ResultsFive percent of invasive breast cancer was metastatic at diagnosis. Compared to patients with earlier stage disease, patients with de novo metastatic disease were significantly more likely to have HER2+ tumors (HR+/HER2+: OR 1.29, 95 % CI 1.17–1.42; HR−/HER2+: OR 1.40, 95 %CI 1.25–1.57, vs. HR+/HER2−). Median survival improved over time, but varied substantially across race/ethnicity (Asians: 34 months; African Americans: 6 months), neighborhood socioeconomic status (SES) (highest: 34 months, lowest: 20 months), and molecular subtype (HR+/HER2+: 45 months; triple negative: 12 months). In a multivariable model, triple negative (RH 2.85, 95 % CI 2.50–3.24) and HR−/HER2+ (RH 1.60, 95 % CI 1.37–1.87) had worse, while HR+/HER2+ had similar, risk of all-cause death compared to HR+/HER2− breast cancer.ConclusionsDe novo metastatic breast cancer was more likely to be HER2+. Among metastatic tumors, those that were HER2+ had better survival than other subtypes.
This paper references
Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases
J. Thigpen (2011)
Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis.
E. Rapiti (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
L. Carey (2006)
Psychological distress among male patients and male spouses: what do oncologists need to know?
G. Goldzweig (2010)
Race, socioeconomic status and stage at diagnosis for five common malignancies
K. Schwartz (2004)
Equitable access to cancer services
J. Mandelblatt (1999)
Factors associated with better survival after surgery in metastatic breast cancer patients
Dhiraj Khadakban (2012)
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
R. Carlson (2012)
Breast cancer in African-American women.
L. Newman (2005)
Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
K. O'Brien (2010)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).
B. Pestalozzi (2006)
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
M. Lund (2008)
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
S. Verma (2013)
SEER) Program (2013) SEER*Stat database: incidence—SEER 18 Regs research Data ? Hurricane Katrina Impacted Louisiana Cases
Facts and controversies in systemic treatment of metastatic breast cancer.
C. Bernard-Marty (2004)
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics.
H. Welch (2015)
Racial differences in outcomes for patients with metastatic breast cancer by disease subtype
I. Vaz-Luis (2015)
Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature
J. Ruiterkamp (2009)
The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes.
A. Lee-Feldstein (2000)
New therapies for metastatic disease addressed in updated NCCN Guidelines for breast cancer.
Race, socioeconomic status, and breast cancer treatment and survival.
C. Bradley (2002)
Molecular portraits of human breast tumours
C. Perou (2000)
Influence of delay on survival in patients with breast cancer: a systematic review
M. Richards (1999)
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype
K. Bauer (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
C. Geyer (2006)
J Clin Oncol
Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
B. Leyland-Jones (2009)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
C. Zimmermann (2014)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
P. Eroles (2012)
Social support and chronic kidney disease: an update.
S. Cohen (2007)
Developing an area-based socioeconomic measure from American Community Survey data
J Yang (2014)
Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study
L. Clegg (2008)
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
D. Slamon (2001)
Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site
B. Cady (2008)
Socioeconomic status and breast cancer incidence in California for different race/ethnic groups
K. Yost (2004)
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
S. Dawood (2010)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
J. Thigpen (2012)
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
M. Edson (2015)
Treatment of breast cancer.
G. Hortobagyi (1998)
Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?
L. Bernstein (2011)
Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer.
D. Lannin (1998)
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
C. Sotiriou (2006)
Stage of breast and cervical cancer diagnosis in disadvantaged neighborhoods: a prevention policy perspective.
N. Breen (1996)
Socioeconomic factors and breast carcinoma in multicultural women
C. Baquet (2000)
Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study
Li Tao (2015)
Does resection of an intact breast primary improve survival in metastatic breast cancer?
S. Khan (2007)
The importance of place of residence in predicting late-stage diagnosis of breast or cervical cancer.
J. Barry (2005)
Surgical Removal of the Primary Tumor Increases Overall Survival in Patients With Metastatic Breast Cancer: Analysis of the 1988-2003 SEER Data
J. Wagner (2008)
Marital status and survival in patients with cancer.
A. Aizer (2013)
Cancer Causes & Control
E. Buiatti (1998)
Breast cancer—facts and figures
James H. Harvey (2013)
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
S. Giordano (2014)
This paper is referenced by
Prognostic outcomes in advanced breast cancer: the metastasis-free interval is important.
T. Shen (2017)
The Integrative Analysis of Gene Expression Profile to Identify Gene Signature in Triple Negative Breast Cancer
M. Desai (2019)
HR+/HER2− Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database
C. Piccinni (2019)
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Gabrielle Planes-Laine (2019)
Breast Cancer Mortality in Older and Younger Patients in California
Li Tao (2018)
Characterization of bone only metastasis patients with respect to tumor subtypes
A. Parkes (2018)
Breast cancer and factors affecting survival rate. Narrative review article
Alaa Ali M. Elzohry (2019)
Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study
Hai-Yun Zhao (2018)
De novo metastatic breast cancer: Subgroup analysis of molecular subtypes and prognosis
L. Zhang (2020)
Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics
J. Ren (2018)
The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis
S. Wu (2017)
Liver Cancer Incidence and Area-Level Geographic Disparities in Pennsylvania—A Geo-Additive Approach
Á. G. Ortiz (2020)
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
N. Howlader (2018)
Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review
J. L. Caswell-Jin (2018)
Genetics of triple-negative breast cancer: Implications for patient care.
Anosheh Afghahi (2016)